Trial Information
Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy
Inclusion Criteria:
- Patients with hepatoma scheduled for treatment with percutaneous ethanol instillation
Exclusion Criteria:
- contraindication for the administration of atropine like
- narrow angle glaucoma
- mechanic stenoses of the GI-tract
- clinically relevant prostatic hypertrophy
- paralytic ileus
- myasthenia gravis
- severe cerebral sclerosis
- acute lung edema
- acute myocardial infarction
- cardiac insufficiency
- hyperthyroidism
- patients with contraindication to undergo percutaneous ethanol instillation
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Outcome Measure:
Occurrence of dysrhythmias
Outcome Time Frame:
during percutaneous ethanol instillation
Safety Issue:
Yes
Principal Investigator
Arnulf Ferlitsch, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Medical University of Vienna
Authority:
Austria: Ethikkommission
Study ID:
atropinePEI
NCT ID:
NCT00575523
Start Date:
October 2003
Completion Date:
January 2008
Related Keywords:
- Arrhythmia
- Respiratory Arrest
- atropine
- percutaneous ethanol instillation
- hepatoma
- bradycardia
- arrhythmia
- Apnea
- Arrhythmias, Cardiac
- Liver Neoplasms
- Carcinoma, Hepatocellular